✦ LIBER ✦

Successful Treatment of Refractory Childhood Pemphgus Vulgaris with Anti-CD20 Monoclonal Antibody (Rituximab)

✍ Scribed by Heidi H. Kong; Neil S. Prose; Russell E. Ware; Russell P. Hall III

Book ID: 109089929
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 83 KB
Volume: 22
Category: Article
ISSN: 0736-8046
DOI: 10.1111/j.1525-1470.2005.00118.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of refractory fludarabine indu

Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-cd20 monoclonal antibody rituximab

✍ R. SWORDS; A. NOLAN; M. FAY; J. QUINN; R. O'DONNELL; P. T. MURPHY 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Rituximab chimeric anti-CD20 monoclonal

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

✍ Peter Brændstrup; Ole W. Bjerrum; Ove J. Nielsen; Bjarne A. Jensen; Nielsaage T. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Schnitzler syndrome: a case report of su

Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab

✍ K.M. Ramadan; H.A. Eswedi; M.R. El-Agnaf 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

Successful treatment of B-cell prolympho

Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody

✍ YasserAbou Mourad; Ali Taher; Aref Chehal; Ali Shamseddine 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 118 KB

Successful treatment and re-treatment of

Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab

✍ M. Herold; A. Schulze; K. Härtwig; G. Anger 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 46 KB

Treatment of B-cell non-Hodgkin's lympho

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have